Home exercise for people with pulmonary hypertension and ILD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study assigns adults with pulmonary hypertension due to interstitial lung disease to a structured home exercise program for 16 weeks, including aerobic and strength training. Participants are assessed at baseline and after the program for functional performance and patient-reported outcomes. The trial also examines feasibility, such as adherence and practicality of delivering the program remotely via smartphone or email. Primary outcomes focus on changes in functional capacity, with secondary outcomes on quality of life and feasibility. Recruitment is centered at the University of Rochester Medical Center, with collaboration from Liquidia Technologies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Follows at University of Rochester Medical Center Pulmonary Hypertension Clinic.
* Adult patients (\>18 years old) with right heart catheterization confirmed pulmonary hypertension interstitial lung disease on stable therapy dosing for at least 30 days.
* Access to a smart phone or email to receive daily messages.
* Clinically stable by the investigator.

Exclusion Criteria:

* Pregnancy.
* Pulmonary Hypertension Groups 1,2,4,5.
* Resting tachycardia \>120 beats/m during screening.
* Inability to walk.
* WHO Functional Class IV
* Lack of access to email or text messaging.
* Participating in a rehabilitation program.

Where it's running

• University of Rochester Medical Center
  Rochester, New York, United States Recruiting

Study contacts

• Study coordinator: Daniel Lachant, DO
• Email: Daniel_Lachant@urmc.rochester.edu
• Phone: 585 273 4608

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Long-Term TPIP Extension for PH-ILD (open-label)

  This study tests whether long-term use of Treprostinil Palmitil Inhalation Powder helps people with pulmonary hypertension due to interstitial lung disease who completed a prior trial.

  Recruiting at 12 sites Phase 3 Insmed Incorporated · Naples, Florida and 11 other locations · NCT07234032

• Once-daily inhaled treprostinil palmitil for pulmonary hypertension linked to interstitial lung disease

  This trial will test whether once-daily inhaled treprostinil palmitil improves exercise ability over 24 weeks in adults with pulmonary hypertension caused by interstitial lung disease.

  Recruiting at 166 sites Phase 3 Insmed Incorporated · Phoenix, Arizona and 185 other locations · NCT07179380

• Registry for patients with pulmonary hypertension linked to interstitial lung disease

  This study is collecting information from patients with pulmonary hypertension linked to interstitial lung disease to see how different treatments affect their health over time.

  Recruiting at 71 sites United Therapeutics · Birmingham, Alabama and 70 other locations · NCT06388421

• Using semaglutide to treat advanced lung disease

  This study is testing if a diabetes and weight loss medication called semaglutide can be safely used by adults with advanced lung diseases to see if it helps them manage their weight better.

  Recruiting Phase 1/2 University of Pennsylvania · Philadelphia, Pennsylvania · NCT05746039

• Using hyperpolarized 129Xe MRI to assess lung function in healthy individuals and those with lung diseases

  This study is testing a special type of MRI using hyperpolarized gas to see how well it can check lung function in both healthy people and those with lung diseases like asthma and COPD.

  Recruiting Phase 1 University of Kansas Medical Center · Kansas City, Kansas · NCT04624490

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.